INTENDED FOR TRADE AND PHARMACEUTICAL PRESS ONLY
Maidenhead, UK, 18th October 2018, AbbVie welcomes the intention expressed by NHS England on 15th October 2018, to maintain HUMIRA® (adalimumab); a specialised biologic medicine for treating a number of inflammatory conditions, as an ongoing treatment option for physicians and patients, as part of the adalimumab tendering strategy, which will start on 1st December 2018.
AbbVie supports the entry of new competitors and the approval of biosimilars that have demonstrated they are as safe and efficacious as their reference products. We remain committed to ensuring that our medicine remains a best value biologic option for the NHS, both now and in the future, and will introduce an interim commercial offer to the NHS to start from the 1st November. It is our position that patients who are stable on their existing biologic therapy should not be switched to another product for non-medical reasons.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.